In May 2024, the Brazilian Senate Committee on Science, Technology, Innovation, and Informatics hosted two public hearings to discuss implementing Regulatory Data Protection (RDP) for pharmaceutical products of human use. The call for hearings (REQ 27/2023) was presented by Senator Izalci Lucas (Liberal Party). While recognizing that regulatory changes would have significant implications for the local industry, the healthcare system, and consumers, Sen. Lucas expressed concern that a lack of measures could discourage investment in R&D.
Recent Posts
- USPTO Says Order Terminating More than 3,000 Applications for Fraudulent Signatures is a Warning for Practitioners
- Export Control Requirements When Assigning Chinese Patents and Patent Applications to Foreign Entities
- Register of Copyrights Shira Perlmutter Jumps into the Great AI Debate at IPWatchdog LIVE
- Checking in With Alice Part II: Takeaways and Predictions
- Other Barks and Bites for Friday, September 27: FTC Appeals Ruling on Noncompete Ban; the TTAB Cancels Four DC and Marvel SUPER HERO Trademarks; OpenAI Agrees to Share Training Data with Authors Suing for Copyright Infringement